Recent advances in drug action and therapeutics: Relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology

British Journal of Clinical Pharmacology

Volumn 57, Issue 4, 2004, Pages 373-387

  Brink, C B ^a   Harvey, B H ^a   Bodenstein, J ^a   Venter, D P ^a   Oliver, D W ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Drug action; G protein coupled receptors; Signal transduction; Therapeutics

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GROWTH ASSOCIATED PROTEIN; NEW DRUG; ORPHAN RECEPTOR; PRESYNAPTIC RECEPTOR; RECEPTOR PROTEIN; RECEPTOR PROTEIN KINASE; RGS PROTEIN; UNCLASSIFIED DRUG;

CHANNEL GATING; DRUG MECHANISM; INTERNALIZATION; MEDICAL EDUCATION; MOLECULAR BIOLOGY; PHARMACOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR DOWN REGULATION; RECEPTOR SENSITIVITY; REVIEW; SIGNAL TRANSDUCTION;

CELL COMMUNICATION; GAP JUNCTIONS; GTP-BINDING PROTEINS; PHARMACEUTICAL PREPARATIONS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 1942487845     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2003.02046.x     Document Type: Review

References (83)

1. Mucklow JC. What knowledge and skills are essential for specialists in clinical pharmacology and therapeutics? Results of a Delphi study. Br J Clin Pharmacol 2002; 53: 341-6.
2. Harvey BH. The neurobiology and pharmacology of depression: a comparative overview of serotonin selective antidepressants. S Afr Med J 1997; 87: 540-52.
3. Lane RM. SSRI-induced extrapyramidal side-effects and atathisia: Implications for treatment. J Psychopharmacol 1998; 12: 192-214.
4. Settle EC. Antidepressant drugs: Disturbing and potentially dangerous adverse effects. J Clin Psychiatry 1998; 59: 25-30.
5. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 85-102.
6. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 466-76.
7. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13.
8. Marshall FH. Heterodimerization of G-protein-coupled receptors in CNS. Curr Opin Pharmacol 2001; 1: 40-4.
9. Neer EJ. Heterotrimeric G proteins organizers of transmembrane signals. Cell 1995; 80: 249-57.
10. Ross EM, Kenakin TP. Pharmacodynamics: Mechanisms of drug action and the relationship between drug concentration and effect. In Goodman and Gilman's the Pharmacological Basis of Therapeutics, 10th edn, eds Hardman JG, Limbird LE. New York: McGraw-Hill 2001, 31-43.
11. Brady AE, Limbird LE. G protein-coupled receptor interacting proteins: Emerging roles in localization and signal transduction. Cell Signal 2002; 14: 297-309.
12. Hur E, Kim K. G protein-coupled receptor signalling and cross-talk. Achieving rapidity and specificity. Cell Signal 2002; 14: 397-405.
13. Gether U, Kobilka BK. G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem 1998; 273: 17979-82.
14. Foord SM. Receptor classification: post genome. Curr Opin Pharmacol 2002; 2: 561-6.
15. Gaulton A, Attwood TK. Bioinformatics approaches for the classification of G-protein-coupled receptors. Curr Opin Pharmacol 2003; 3: 114-20.
16. Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett 2002; 520: 97-101.
17. Devi LA. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol Sci 2001; 22: 532-7.
18. Ahlquist RP. A study of adrenotropic receptors. Am J Physiol 1948; 153: 586-600.
19. Spedding M, Bonner TI, Watson SP, International Union of Pharmacology. XXXI. Recommendations for the Nomenclature of Multimeric G Protein-Coupled Receptors. Pharmacol Rev 2002; 54: 231-2.
20. Nothacker H, Reinscheid RK, Civelli O. From receptor to endogenous ligand. In Receptors: Structure and Function, 2nd edn, eds Stanford, C, Horton, R. New York: Oxford University Press 2001, 41-64.
21. Shaaban S, Benton B. Orphan G protein-coupled receptors: from DNA to drug targets. Curr Opin Drug Discov Devel 2001; 4: 535-47.
22. Katugampola S, Davenport A. Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system. Trends Pharmacol Sci 2003; 24: 30-5.
23. Bennett T, Gardiner SM. Fostering orphan receptors: an indispensable role for integrative, in vivo, haemodynamic studies. Curr Opin Pharmacol 2003; 3: 140-5.
24. Willson TM, Moore JT. Genomics versus orphan nuclear receptors - a half-time report. Mol Endocrinol 2002; 16: 1135-44.
25. Kenakin T. Agonist-receptor efficacy I. mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci 1995; 16: 188-92.
26. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 2001; 15: 598-611.
27. Strange PG. Three-state and two-state models: Recent models of receptor function raises issues about the conformations of their coupling. Trends Pharmacol Sci 1998; 19: 85-6.
28. Leff P. The two-state model of receptor activation. Trends Pharmacol Sci 1995; 16: 89-97.
29. Leff P, Scaramellini C, Law C, McKechnie K. A three-state receptor model of agonist action. Trends Pharmacol Sci 1997; 18: 355-62.
30. Sonnenblick EH, Frishman WH. Cardiovascular Pharmacoptherapeutics: a Companion Handbook. New York: McGraw-Hill 1998, 37.
31. Strange PG. Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci 2002; 23: 89-95.
32. 2a-adrenergic receptor. Mol Pharmacol 2001; 59: 532-42.
33. Langer SZ. 25 Years since the discovery of presynaptic receptors: present knowledge and future perspectives. Trends Pharmacol Sci 1997; 18: 95-9.
34. MacDermott AB, Role LW, Siegelbaum SA. Presynaptic ionotropic receptors and the control of transmitter release. Annu Rev Neurosci 1999; 22: 443-85.
35. 2-receptors controlling neurotransmitter release from postganglionic sympathetic neurones. Prog Brain Res 1999; 120: 173-82.
36. Hoffman BB, Taylor P. Neurotransmission: The autonomic and somatic motor nervous systems. In Goodman and Gilman's the Pharmacological Basis of Therapeutics, 10th edn, eds Hardman JG, Limbird LE. New York: McGraw-Hill 2001, 115-53.
37. Langer SZ. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 1980; 32: 337-62.
38. Langer SZ, Lehmann J. In: Trendelenburg, U, Weiner, N. Handbook of Experimental Pharmacology: Catecholamine I, Vol. 85. Berlin, Springer-Verlag, 1988, 429-507.
39. Starke K. Presynaptic receptors. Annu Rev Pharmacol Toxicol 1981; 21: 7-30.
40. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In Goodman and Gilman's the Pharmacological Basis of Therapeutics, 10th edn, eds Hardman, JG, Limbird, LE. New York: McGraw-Hill 2001, 447-83.
41. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 2003; 13: 57-66.
42. Sierra DA, Popov S, Wilkie TM. Regulators of G-protein Signaling in Receptor Complexes. Trends Cardiovasc Med 2000; 10: 263-8.
43. Lim WK, Neubig RR. Selective inactivation of guanine-nucleotide-binding regulatory protein (G-protein) α and βγ subunits by urea. Biochem J 2001; 354: 337-44.
44. Neubig RR. Membrane organization in G-protein mechanisms. FASEB J 1994; 8: 939-46.
45. Wieland T, Chen CK. Regulators of G-protein signalling: a novel protein family involved in timely deactivation and desensitization of signalling via heterotrimeric G proteins. Naunyn Schiedebergs Arch Pharmacol 1999; 360: 14-26.
46. oα, is tissue-specific and age-dependent in the rat. Gene 2002; 296: 249-55.
47. Neubig RR, Siderovski DP. Regulators of G-protein signalling as new central nervous system drug targets. Nat Rev Drug Discov 2002; 1: 187-97.
48. Zong H, Neubig RR. Regulator of G protein signaling proteins: Novel multifunctional drug targets. J Pharmacol Exp Ther 2001; 297: 837-45.
49. Mirnics K, Middleton FA, Lewis DA, Levitt P. Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci 2001; 24: 479-86.
50. Tekumalla PK, Calon F, Rahman Z, et al. Elevated levels of ΔFosB and RGS9 in striatum in Parkinson's disease. Biol Psychiatry 2001; 50: 813-6.
51. Ji TH, Grossmann M, Ji I. G protein-coupled receptors. I. Diversity of receptor-ligand interactions. J Biol Chem 1998; 273: 17299-302.
52. 2-adrenergic, muscarinic, and opiate receptors. Mol Pharmacol 1992; 43: 434-43.
53. 2-adrenergic receptor suntypes in cells and tissues. Pharmacol Ther 1999; 84: 193-205.
54. Neubig RR. Specificity of receptor-G protein coupling: Protein structure and cellular determinants. Neuroscience 1998; 9: 189-97.
55. Selbie LA, Hill SJ. G protein-coupled receptor cross-talk: the fine-tuning of multiple receptor-signalling pathways. Trends Pharmacol Sci 1998; 19: 87-93.
56. 2A-adrenergic receptor to multiple G-proteins. J Biol Chem 1994; 269: 5730-4.
57. 2A-adrenergic receptors s to two G proteins with opposing effects. J Biol Chem 1992; 267: 15795-801.
58. Sanders-Bush E, Mayer SE. 5-hydroxytryptamine (serotonin). Receptor agonists and antagonists. In Goodman and Gilman's the Pharmacological Basis of Therapeutics, 10th edn, eds Hardman JG, Limbird LE. New York: McGraw-Hill 2001, 269-90.
59. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry (Suppl) 1993; 54: 3-15.
60. Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002; 109: 451-60.
61. 1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 2003; 3: 1-8.
62. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP. Effector pathway-dependent R. e. at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 1998; 54: 94-104.
63. s. J Pharmacol Exp Ther 2000; 294: 539-47.
64. Kenakin T. Agonist-receptor efficacy. II. agonist trafficking of receptor signals. Trends Pharmacol Sci 1995; 16: 232-8.
65. Brink CB. Protean behavior by agonists. Role of 'agonist-directed trafficking of receptor signaling'. Trends Pharmacol Sci 2002; 23: 454-5.
66. Kenakin T. Pharmacological proteus? Trends Pharmacol Sci 1995; 16: 256-8.
67. Roth BL, Willins DL, Kroeze WK. G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse. Drug Alcohol Depend 1998; 51: 73-85.
68. 2A receptors by agonists and antagonists. Brain Res Bull 2001; 56: 441-51.
69. Von Zastrow M. Endocytosis and downregulation of G protein-coupled receptors. Parkinsonism Relat Disord 2001; 7: 265-71.
70. Tsao PI, von Zastrow M. Diversity and specificity in the regulated endocytic membrane trafficking of G-protein-coupled receptors. Pharmacol Ther 2001; 89: 139-47.
71. Polastron J, Meunier JC, Jauzac P. Chronic morphine induces tolerance and desensitization of mu-opioid receptor but not down-regulation in rabbit. Eur J Pharmacol 1994; 266: 139-46.
72. Chen JJ, Dymshitz J, Vasko MR. Regulation of opioid receptors in rat sensory neurons in culture. Mol Pharmacol 1997; 51: 666-73.
73. Patel MB, Patel CN, Rajashekara V, Yoburn BC. Opioid agonists differentially regulate μ-opioid receptors and trafficking proteins in vivo. Mol Pharmacol 2002; 62: 1464-70.
74. Zhang J, Ferguson SG, Barrak LS, et al. Role for G protein-coupled receptor kinase in agonist-specific regulation of μ-opioid receptor responsiveness. Proc Natl Acad Sci USA, 1998; 95: 7157-62.
75. ++ channels during opioid tolerance and supersensitivity in rats. J Pharmacol Exp Ther 1995; 274: 1538-44.
76. Cahill CM, Morinville A, Hoffert C, O'Donnel D, Beaudet A. Up-regulation and trafficking of δ opioid receptor in a model of chronic inflammation: Implications for pain control. Pain 2003; 101: 199-208.
77. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49.
78. Johnson JA, Terra SG. Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics. Pharm Res 2002; 19: 1779-87.
79. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, Wood AJ. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001; 345: 1030-5.
80. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999; 65: 519-25.
81. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, Lemanske RF Jr, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN, National Heart, Lung and Blood Institute's Asthma Clinical Research Network. Effect of polymorphism of the beta (2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 2001; 124: 183-6.
82. Gurevich I, Tamir H, Arango V, Dwork AJ, Mann JJ, Schmauss C. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 2002; 34: 349-56.
83. Iiri T, Farfel Z, Bourne HR. G-protein diseases furnish a model for the turn-on switch. Nature 1998; 394: 35-8.